{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":"Lymphocytes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"Hyperkalemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}],"title":"Hyperglycemia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"Clinical laboratory evaluations included hematology, chemistry, and liver and renal functioning.","groups":[{"description":"Participants in 2 arms were enrolled sequentially. The first group of participants received elotuzumab intravenously at a dose of 20 mg/kg on Days 1 and 8 per 28-day cycle for Cycle 1 and then on Day 1 only in subsequent cycles.","id":"OG000","title":"Elotuzumab, 20 mg/kg"},{"description":"Participants in the second group received elotuzumab intravenously at a dose of 10 mg/kg weekly per 28-day cycle in Cycles 1 and 2, then on Days 1 and 15 in subsequent cycles.","id":"OG001","title":"Elotuzumab, 10 mg/kg"},{"description":"All participants on Elotuzumab therapy. Comprised of both the 20mg/kg and 10mg/kg arms","id":"OG002","title":"Elotuzumab, All Dosages"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"From date of first dose to date of last dose plus 60 days (assessed up to August 2017, approximately 59 months","title":"Number of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality","type":"SECONDARY","unitOfMeasure":"Participants"}